Polypharmacy in Psychiatry Practice, Volume II

Use of Polypharmacy in the "Real World"

Paperback Engels 2015 9789401782562
Verwachte levertijd ongeveer 9 werkdagen

Samenvatting

Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.

Specificaties

ISBN13:9789401782562
Taal:Engels
Bindwijze:paperback
Uitgever:Springer Netherlands

Lezersrecensies

Wees de eerste die een lezersrecensie schrijft!

Inhoudsopgave

<p>About the Editor<p>Preface  </p><p>Contributors to Volume II</p><p>Part 1. Antipsychotic polypharmacy  </p><p>1.      Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? Peter F. Buckley<p>2.      Antipsychotic polypharmacy in USA.  Anand K. Pandurangi, John Vernon</p><p>3.      Antipsychotic polypharmacy in Czech Republic and in Ukraine. Viktor P. Samokhvalov, Oxana Samokhvalova, Viktoria  A. Verbenko, Georgij N. Verbenko</p><p>4.      Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice. Lucio Ghio, Werner Natta, Simona Gotelli, Luigi Ferrannini</p><p>5.      Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? KH Yong, Norman Sartorius, Kang Sim</p><p>6.      Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura <p>7.      Clozapine combinations in treatment-resistant schizophrenia patients. Vladimir Lerner and Chanoch Miodownik</p><p>8.      Metabolic syndrome and antipsychotic polypharmacy. Fuminari Misawa, Fujii Yasuo, Yasuyuki Okumura, Hiroto Ito</p><p> </p><p>Part 2. Polypharmacy for other psychiatric conditions</p><p>9.      Evidence based combination therapy for bipolar disorder. Stamatia Magiria, Melina Siamouli, Xenia Gonda, Apostolos Iacovides, Konstantinos N. Fountoulakis</p><p>10.  Antidepressant combination strategies for major depressive disorder. André F. Carvalho, Danielle S. Macêdo, Thomas N. Hyphantis, Roger S. McIntyre<p>11.  Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk. Arun V. Ravindran and Tricia L. da Silva</p>12.  Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? Frederike Schirmbeck and Mathias Zink</p><p>13.  Polypharmacy and potentially inappropriate medication use among elders with dementia. Jan Lužný<p>14.  The role of polypharmacy in bipolar disorder treatment guidelines. Heinz Grunze</p><p>Appendix             Rena Kurs<p>1.      Annotated bibliography on polypharmacy</p><p>2.      List of Psychotropic Medications  </p><p>Contents to Volume I </p><p>Contributors to Volume I</p><p>Index</p>

Managementboek Top 100

Rubrieken

    Personen

      Trefwoorden

        Polypharmacy in Psychiatry Practice, Volume II